Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).

@article{Lee2014ComparisonOC,
  title={Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).},
  author={Ji Yun Lee and Sung Hee Lim and Kwai Han Yoo and M. J. Kim and Sungmin Kim and Hyun Ae Jung and Jong-Mu Sun and Sung-Bae Kim and Keon Uk Park and Hoon-Kyo Kim and Dae Sik Hong and Jun Suk Kim and Seong-Geun Kim and Seong Yoon Yi and Hwan-Jung Yun and Myung Soo Hyun and Hyo Jung Kim and Keunchil Park and Yong Chan Ahn and Myung-Ju Ahn},
  journal={Journal of Clinical Oncology},
  year={2014},
  volume={32},
  pages={6023-6023}
}
  • J. Lee, S. Lim, M. Ahn
  • Published 20 May 2014
  • Medicine
  • Journal of Clinical Oncology
6023 Background: Concurrent chemoradiation therapy (CCRT) with every 3 week schedule of cisplatin is the standard treatment for locally advanced nasopharyngeal carcinoma (NPC), but concerns have been raised about treatment-related complications. We conducted a randomized phase II non-inferiority study of CCRT with three week versus weekly cisplatin to compare the efficacy and toxicity profiles. Methods: From September 2009 through August 2011, 111 patients with locally advanced NPC who have…